Venetoclax: a new weapon to treat high-risk CLL

3report that venetoclax, a specifi c inhibitor of BCL2, broadens the opportunity to eff ectively treat patients with relapsed or refractory chronic lymphocytic leukaemia harbouring TP53 disruption. Although heterogeneous design and diff erent inclusion criteria limit indirect comparisons across trials, the proportion of patients achieving an overall response (79·4% [95% CI 70·5–86·6]) and the 12-month progression free survival (72·0% [95% CI 61·8–79·8]) in patients given venetoclax recorded in this study are similar to those previously reported with kinase inhibitors in the same patient population. 4,5